Tasty, We’ll said. I agree with everything you stated except I don’t believe it’s time to abandon the US market. Especially without trying an AG first. Play the generic game if that’s what it takes to compete fairly on the same tier. Who wouldn’t chose the branded generic when given the choice. If AMRN partnered with TEVA for an AG, TEVA would have the largest available supply and payer/pharmacy contacts and contracts to successfully compete with and possibly dominate other generics. AMRN would continue with brand V if they chose. After that, AMRN could launch a branded and or AG FDC. AMRN could also pursue an indication for 1.8 gram dose to to treat endothelial dysfunction or other indication. I’m not ready to throw in the towel on the US market just yet.
News 
Market Data 
Discover 
